Payment & Shipping Terms:
|Type:||Angiotensin II Receptor Antagonist||Use:||Antihypertensive|
|Trade Terms:||FOB CNF CIF DAP DDU||Shipping:||DHL TNT FedEx HKEMS UPS Sea Air|
Valsartan Medicine Raw Material for Treat Posterior Myocardial Infarction primary hypertension
Valsartan is an angiotensin II receptor antagonist antihypertensive drugs, the drug is a make angiotensin Ⅱ type 1 ( AT1 ) receptor blockade, angiotensin Ⅱ plasma levels, stimulate non - sealing AT2 receptors, against the effect of AT1 receptor at the same time, so as to achieve to dilate blood vessels the effect of lowering blood pressure.
In the United States, valsartan is a drug used to treat hypertension, congestive heart failure and post - myocardial infarction.
Switzerland ciba - fine base company research and development production of the generation of valsartan in 1995 and 1996, respectively, to obtain a patent in the United States and Europe, and in July 1996 for the first time to market in Germany, then gradually in Europe, America, Japan. Valsartan has the characteristics of stable hypotension effect and small toxicity.
Valsartan is used to treat high blood pressure, congestive heart failure, and to reduce death for people with left ventricular dysfunction after having had a heart attack.
In people with type II diabetes and high blood pressure or albumin in the urine, valsartan is used to slow the worsening and the development end-stage renal disease.
Mechanism of action
Valsartan blocks the actions of angiotensin II, which include constricting blood vessels and activating aldosterone, to reduce blood pressure. The drug binds to angiotensin type I receptors ( AT1 ), working as an antagonist. This mechanism of action is different than the ACE inhibitor drugs, which block the conversion of angiotensin I to angiotensin II.
Since valsartan acts at the receptor, it can provide more complete angiotensin II antagonism since angiotensin II is generated by other enzymes as well as ACE. Also, valsartan does not affect the metabolism of bradykinin like ACE inhibitors do.
|Appearance||White to almost white powder||White powder|
|Identification||Infrared absorption: The IR spectrum is consistent with that obtained with the reference||Conforms|
|The retention time of the major peak in the chromatogram of the Assay preparation corresponds to that in the chromatogram of the Standard preparation, as obtained in the Assay.||Conforms|
|Residue on ignition||NMT 0.1%||0.07%|
|Heavy metals||NMT 0.001%||Complies|
|Related compounds ( HPLC )||Compound A NMT 1.0%||0.59%|
|Compound B NMT 0.2%||0.04%|
|Compound C NMT 0.1%||0.05%|
|Any other individual impurity NMT 0.1% ( excluding compound A )||0.07%|
|Total impurities NMT 0.3% ( excluding compound A )||0.16%|
|Residual solvents ( GC )||Ethyl acetate NMT 5000ppm||305ppm|
|Dichloromethane NMT 600ppm||Undetected|
|Methanol NMT 3000ppm||Undetected|
|N, N - Dimethylformamide NMT 880PPM||Undetected|
|Assay ( HPLC )||98.0%~102.0%||99.65%|